-
Scandic Trust Group strengthens sales network with First Idea Consultant
-
Kolisi 100th Test 'no distraction' for Erasmus' South Africa
-
Teetering Belgian government given more time to agree budget
-
Merz backs EU plan to protect steel sector from Chinese imports
-
New Zealand make Scotland changes after Barrett brothers' injuries
-
'Roy of the Rovers story' -- Farrell handed Ireland debut for Japan Test
-
Stones backs Man City team-mate Foden to pose England dilemma for Tuchel
-
Djokovic to face Alcaraz in ATP Finals groups
-
Facing climate 'overshoot', world heads into risky territory
-
Springbok skipper Kolisi to play 100th Test against France
-
Typhoon Kalmaegi hits Vietnam after killing 140 in Philippines
-
Bank of England leaves rate unchanged before UK budget
-
Germany recall Sane, hand El Mala debut for World Cup qualifers
-
India thump Australia to take 2-1 lead in T20 series
-
Cameroon's Biya, world's oldest president, sworn in for 8th term
-
Flick holding firm on Barca high line despite defensive woes
-
Battered US businesses eye improved China trade at Shanghai expo
-
France opt for Le Garrec as Dupont replacement for 'best team ever' South Africa
-
Drugmaker AstraZeneca profit jumps as US business grows
-
'Vibe coding' named word of the year by Collins dictionary
-
Vietnam evacuates thousands from coast ahead of Typhoon Kalmaegi
-
European stocks fall after gains in Asia, US
-
MotoGP legend Agostini admires Marc Marquez's 'desire to win'
-
Nepal searches for avalanche victims
-
Hezbollah rejects any negotiations between Lebanon and Israel
-
Chapman blitz leads Black Caps to tight T20 victory over West Indies
-
France urges EU to sanction Shein platform
-
France opt for Le Garrec as Dupont replacement for South Africa Test
-
Turmoil in tiaras at Miss Universe pageant in Thailand
-
Probe into Thales defence group looking at Indonesian contract
-
US to cancel flights as longest govt shutdown drags on
-
Home in Nigeria, ex-refugees find themselves in a war zone
-
Doncic's Lakers hold off Wembanyama's Spurs, Blazers silence Thunder
-
For Turkey's LGBTQ community, draft law sparks existential alarm
-
Musk's $1 trillion pay package to face Tesla shareholder vote
-
Tonga rugby league star out of intensive care after seizure
-
Argentine ex-president Kirchner goes on trial in new corruption case
-
Dams, housing, pensions: Franco disinformation flourishes online
-
Endo returns as Japan look to build on Brazil win
-
Franco captivates young Spaniards 50 years after death
-
German steel industry girds for uncertain future
-
IPL champions Bengaluru could be sold for 'as much as $2 billion'
-
Budget impasse threatens Belgium's ruling coalition
-
New Zealand ex-top cop admits to having material showing child abuse, bestiality
-
BoE set for finely balanced pre-budget rate call
-
Australian kingpin obtains shorter sentence over drug charge
-
Weatherald's unenviable Ashes task: fill giant hole at top left by Warner
-
Ovechkin first to score 900 NHL goals as Capitals beat Blues
-
On Mexico City's streets, vendors fight to make it to World Cup
-
Asian markets bounce from selloff as US jobs beat forecasts
Mice trial raises hopes for 'on demand' male contraceptive
If women have the "morning after" pill, could men one day have an "hour before" pill?
A new drug candidate renders male mice infertile within an hour and wears off in less than a day, an experimental study said Tuesday, potentially pointing towards a future "on-demand" male contraceptive.
The potential drug, which has not been tested in humans and remains years away from possibly becoming available, joins a growing number of male contraceptives in development.
However there are currently only two options available for men: condoms and vasectomies.
Previous drugs have struggled partly because the bar for side effects is believed to be far higher for men -- because they do not risk getting pregnant -- as well as a lack of interest from the pharmaceutical industry.
"For women, right now all the burden of contraception is on us," Melanie Balbach, a pharmacology researcher at Weill Cornell Medicine in the US, told AFP.
"We want new options," said Balbach, the lead author of the study published in Nature Communications.
The team of researchers targeted an enzyme called soluble adenylyl cyclase, which acts as the "on switch" for sperm, said study co-author Jochen Buck, also of Weill Cornell Medicine.
If the enzyme is switched off, the sperm can no longer move, he said.
Across several different tests, the researchers showed that a compound which blocks the enzyme renders mice sperm immobile in 30 minutes to an hour.
The compound was 100 percent effective in preventing pregnancy within the first two hours, dropping to 91 percent in the first three hours, the study said.
After 24 hours, the mice sperm moved like normal again.
- 'Eye-catching advantage' -
The researchers hope are aiming for a single non-hormonal pill that works in under an hour and lasts six to 12 hours, Buck said.
This would be much different to other options under development, such as a hormonal gel currently going through human trials, which all take weeks or months to start and stop working.
No side effects were noticed in the mice. Previous research has suggested that infertile men who had their soluble adenylyl cyclase enzyme permanently switched off had an increased rate of kidney stones.
Buck said this was the result of their enzyme always being off -- which would not be the case for men taking an on demand pill.
The researchers hope to hold the first trials on humans within three years, with a final product possibly up to eight years away, Buck said.
Susan Walker, an expert in contraception at the UK's Anglia Ruskin University not involved in the research, said she was a "little sceptical" a pill would actually make it to market as so many other efforts have fallen short.
But the "eye-catching advantage" of almost immediate effectiveness offered "the possibility of seeing a sexual partner take a pill," she said.
The consultancy Desire Line is working on forecasting the potential uptake of a range of male contraceptive products, according to its founder Steve Kretschmer.
"Initial estimates indicate in the United States that uptake for an on-demand pill which has quick onset of action and 1-2 days duration of action could be about triple that of Viagra when it was initially launched," he told AFP.
B.Mahmoud--SF-PST